Inovio Pharmaceuticals Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Roundhill NVDA WeeklyPay ETF trades at $37.17 (market cap $119.10M). The key difference: Inovio Pharmaceuticals Inc and Roundhill NVDA WeeklyPay ETF are close in size by market cap, and Roundhill NVDA WeeklyPay ETF is more actively traded (44,838 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Roundhill NVDA WeeklyPay ETF for 50 Days on average.
| INO | NVDW | |
|---|---|---|
Market Cap | $112.19M | $119.10M |
Volume | 3,201,278 | 44,838 |
Sector | Health | Income / Options Overlay |
52-Week High | $2.65 | $52.33 |
52-Week Low | $0.66 | $31.88 |
Typical Hold Time | 43 Days | 50 Days |
Enterprise Value | $83.51M | — |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →